All appeals filed by both the plaintiff and the defendant are dismissed.

Expenses for appeal shall be borne individually by each person.

Purport of claim and appeal

(b).

1. The reasoning for the court’s explanation regarding this case is as follows: (a) the Plaintiff: (b) went out under the medical personnel’s permission on May 22, 2015; (c) the medical personnel at the Defendant hospital was confirmed as 39.2C; and (d) the medical personnel at the Defendant hospital administered piracy control to the Plaintiff on May 22, 2015; and (c) the medical personnel at the Defendant hospital continued infection and cooperation with the blood cultivation test on May 22, 2015; and (d) on May 28, 2015, the Defendant hospital’s medical personnel conducted the blood cultivation test on May 28, 2015, with the exception of the Merecinant lusium No. 201, Mar. 25, 2015, the Plaintiff 2010 and the Merecinant lusium No. 301, citing each part of the judgment on the Merecinus Ma2015, hereinafter referred to “M15,”.

2. The addition;

A. The lifespan of the Plaintiff’s mission, the Plaintiff’s claim for future treatment costs, is ordinarily 10 to 15 years, and as of October 22, 2015, the Plaintiff’s age was 67 years and 11 years, and the average life expectancy of Korean women at the same age was 21.02, and thus, it is necessary to re-consignate the artificial sludge in the future.

1,882,736 won (the cost of treatment incurred by the plaintiff for re-exploiting to the right line in Seoul National University Hospital from April 19, 2016 to April 29, 2016 is KRW 3,294,954. Thus, the above amount can be calculated as the cost of re-exploitation in the future. If calculating the intermediate interest by deducting it, it is 1,882,736 won 3,294,954 x 0.5714 (the past 15 years). Thus, the defendant is also obligated to pay the plaintiff the above 1,82,736 won as the cost of future treatment.

B. The results of fact-finding on the Chief of the Seoul National University Hospital are examined.